CD274 and non-small cell lung carcinoma: In those trials, more than 4500 patients with stage IB-IIIA NSCLC have been randomised (regardless of PD-L1 status) to receive one year of ICI or placebo (PEARLS, BR31, CANOPY-A) or one year of ICI vs. observation (ANVIL and IMpower-010) after standard CT, if indicated.